drugset / Trial / NCT02267642
A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis
NaSingle-groupOpen-labelTreatment
Summary
To evaluate efficacy, safety, tolerability, and immunogenicity of AbGn-168H administered intravenously in patients with active psoriatic arthritis.
Timeline
- Start
- 2015-01
- Primary completion
- 2015-10
- Completion
- 2016-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neihulizumab | Monoclonal antibody | — | Intravenous |